Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR8008 vs Fluconazole in Recurrent Vulvovaginal Candidiasis
NCT05074602Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oteseconazole in recurrent vulvovaginal candidiasis (RVVC), sponsored by Hengrui. Status: unknown.
02
Drugs
oteseconazole
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on NCT05074602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074602.